{"analyses":[{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.68","estimateComment":"Reference level = Chemoradiation","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8910","paramType":"Hazard Ratio (HR)","paramValue":"1.03","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"26.3","upperLimit":"NA","value":"38.5"},{"comment":"Not reached","groupId":"OG001","lowerLimit":"27.9","upperLimit":"NA","value":"40.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"description":"Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated using the Kaplan-Meier method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. One-year rates are provided. Analysis occurred after 102 progression-free survival events were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin","id":"OG000","title":"Chemoradiation"},{"description":"Metformin plus 60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin","id":"OG001","title":"Metformin + Chemoradiation"}],"paramType":"NUMBER","populationDescription":"Eligible participants","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 47.2 months.","title":"Percentage of Participants Alive (Overall Survival)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}